1 / 39

Patented Medicine Prices Review Board Regulatory Affairs and Outreach Branch

Patented Medicine Prices Review Board Regulatory Affairs and Outreach Branch . Outreach Sessions Montreal, November 22, 2012 Toronto, November 23, 2012. Overview. Regulatory Filing – Latest Changes Form 1 Form 2 Block 1, 2, 3 Interim Maximum Average Potential Price (MAPP) DIP Methodology

karik
Download Presentation

Patented Medicine Prices Review Board Regulatory Affairs and Outreach Branch

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Patented Medicine Prices Review BoardRegulatory Affairs and Outreach Branch Outreach Sessions Montreal, November 22, 2012 Toronto, November 23, 2012

  2. Overview Regulatory Filing – Latest Changes Form 1 Form 2 Block 1, 2, 3 Interim Maximum Average Potential Price (MAPP) DIP Methodology Simplified Regular PMPRB 101

  3. Regulatory Filing Latest Changes in Form 1 and Form 2 Block 1, 2, 3

  4. Changes in Form 1

  5. Changes in Form 1

  6. Changes in Form 1

  7. Changes in Form 1

  8. Changes in Form 2, Block 1, 2, 3

  9. Changes in Form 2, Block 1, 2, 3

  10. Changes in Form 2, Block 1, 2, 3

  11. Interim Maximum Average Potential Price (MAPP)

  12. Interim MAPP • Compendium of Policies, Guidelines and Procedures, Schedule 5, Section 1.3 • 1.3 When the new patented drug product is sold in fewer than five countries at the time it is first sold in Canada, the median international price will be calculated on an interim basis. At the end of three years or when the same patented drug product with the same strength and dosage form is sold in at least five countries, whichever occurs first, Board Staff will re-determine the median international price. Whenever this occurs, the drug product’s Non-Excessive Average Price will be the lower of: • The re-determined median international price, and • The Non-Excessive Average Price derived from the ordinary application of the CPI-Adjustment Methodology (see Schedule 9).

  13. MIPC in Introductory Price Tests Introductory Price Tests Level of Therapeutic Improvement Breakthrough MIPC If no comparator is identified Or if price of comparator is excessive Or if cannot derive dosage regimen Or If no public price is found MIPC Substantial Improvement • Higher of: • Top of TCC - MIPC Moderate Improvement Higher of: - Mid point (Top of TCC and MIPC) - Top TCC Top of TCC Slight/No Improvement Lower of: - Bottom of TCC - MIPC

  14. Interim MAPP: Example 1 (MIPC) • Drug product A introduced in March 2010 • Pivotal test establishing the MAPP at introduction : Median International Price Comparison (MIPC) test • In 2010, Drug product A is sold in Italy ($10) and in the US ($20) • Interim MIPC = Interim MAPP (2010) = $15

  15. Interim MAPP: Example 1 (MIPC) • Scenario 1: Three years (2013) • In 2011, 2012 and 2013, drug A still sold in only 2 countries MIPC = $15 • Post-Interim MAPP is set by MIPC • 2013 N-NEAP (based on CPI-Adjustment Methodology) = $14 • Impact on future requests for DIP application: IBP remains at $15 Post-Interim MAPP (2013) = $15 Final 2013 N-NEAP = $14

  16. Interim MAPP: Example 1 (MIPC) • Scenario 2: Five countries (lower PI-MAPP) • In 2012, Drug product A is now sold in 5 countries: Italy ($10), France ($10), Germany ($10), Switzerland ($10), US ($20) MIPC = $10 • Post-Interim MAPP is set by MIPC • N-NEAP (based on CPI-Adjustment Methodology) in 2012 is $13 • If 2012 N-ATP > Final 2012 N-NEAP, Company is given one year to adjust N-ATP to be ≤ 2013 N-NEAP (2012 N-NEAP + CPI) • Impact on future requests for DIP application: IBP reset in 2012 to $10 Post-Interim MAPP (2012) = $10 Final 2012 N-NEAP = $10

  17. Interim MAPP: Example 1 (MIPC) • Scenario 3 : Five countries (higher PI-MAPP) • In 2012, Drug product A is now sold in 5 countries: Italy ($10), France ($17), Germany ($17), Switzerland ($17), US ($20) MIPC = $17 • Post-Interim MAPP is set by MIPC • N-NEAP (based on CPI-Adjustment Methodology) in 2012 is $13 • Impact on future requests for DIP application: IBP remains at $15 Post Interim MAPP (2012) = $17 Final 2012 N-NEAP = $13

  18. Interim MAPP: Example 2 (Higher of TCC and MIPC) • Drug product A introduced in March 2010 • Level of therapeutic improvement : Substantial Improvement • Test establishing the MAPP at introduction : Higher of top of • Therapeutic Class Comparison (TCC) test and the MIPC test • In 2010, top of TCC = $10 • A is sold in Italy ($10) and in the US ($20) Interim MIPC = $15 • In this case, the Interim MAPP is set by the Interim MIPC • Interim MAPP (2010) = $15

  19. Interim MAPP: Example 2 (Higher of TCC and MIPC) • Scenario 1 : Three years (2013) • Drug product A still sold in only 2 countries. MIPC =$15 • Post-Interim MAPP is set by MIPC • N-NEAP (based on CPI-Adjustment Methodology) = $14 • Impact on future requests for DIP application: IBP remains at $15 Post-Interim MAPP (2013) = $15 Final 2013 N-NEAP = $14

  20. Interim MAPP: Example 2 (Higher of TCC and MIPC) • Scenario 2 : Five countries (lower PI-MAPP) • In 2012, Drug product A now sold in 5 countries: Italy ($10), France ($9), • Germany ($9), Switzerland ($9), US ($20) MIPC = $9 • Post-Interim MAPP is set by TCC ($10) • N-NEAP (based on CPI-Adjustment Methodology) in 2012 is $13 • If 2012 N-ATP > Final 2012 N-NEAP ($10) Company will be given one year to adjust N-ATP to be ≤ 2013 N-NEAP (2012 N-NEAP + CPI) • Impact on future requests for DIP application: IBP reset in 2012 to $10 Post-Interim MAPP (2012) = $10 Final 2012 N-NEAP = $10

  21. Interim MAPP: Example 2 (Higher of TCC and MIPC) • Scenario 3 : Five countries (higher PI-MAPP) • In 2012, Drug product A now sold in 5 countries: Italy ($10), France ($17), • Germany ($17), Switzerland ($17), US ($20) MIPC = $17 • Post-Interim MAPP is set by MIPC • N-NEAP (based on CPI-Adjustment Methodology) in 2012 is $13 • Impact on future requests for DIP application: IBP remains at $15 Post-Interim MAPP (2012) = $17 Final 2012 N-NEAP = $13

  22. Interim MAPP: Example 3 (Higher of TCC and Mid Point) • Drug product A introduced in March 2010 • Level of therapeutic improvement : Moderate Improvement • Test establishing the MAPP at introduction : Higher of top of TCC test and Mid Point (Average of top of TCC and MIPC) • In 2010, Top of TCC = $10 • Drug product A is sold in Italy ($10) and the US ($20) Interim MIPC = $15 • Mid Point = $12.50 • Interim MAPP is set by Mid Point • Interim MAPP (2010) = $12.50

  23. Interim MAPP: Example 3 (Higher of TCC and Mid Point) • Scenario 1: Three years (2013) • Drug product A is still only sold in 2 countries MIPC =$15 • Mid Point = $12.50 • Post-Interim MAPP is set by Mid Point • N-NEAP (based on CPI-Adjustment Methodology) in 2013 is $13 • If 2013 N-ATP > Final 2013 N-NEAP ($12.50) Company will be given one year to adjust N-ATP to be ≤ 2014 N-NEAP (2013 N-NEAP + CPI) • Impact on future requests for DIP application: IBP remains at $12.50 Post-Interim MAPP (2013) = $12.50 • Final 2013 N-NEAP = $12.50

  24. Interim MAPP: Example 3 (Higher of TCC and Mid Point) • Scenario 2: Five countries (lower PI-MAPP) • In 2012, Drug product A now sold in 5 countries: Italy ($10), France ($9), • Germany ($9), Switzerland ($9), US ($20) MIPC = $9 • Mid Point = $9.50 • Post-Interim MAPP is set by TCC ($10) • N-NEAP (based on CPI-Adjustment Methodology) in 2012 is $13 • If 2012 N-ATP > Final 2012 N-NEAP ($10) Company will be given one year to adjust N-ATP to be ≤ 2013 N-NEAP (2012 N-NEAP + CPI) • Impact on future requests for DIP application: IBP reset in 2012 to $10 Post-Interim MAPP (2012) = $10 Final 2012 N-NEAP = $10

  25. Interim MAPP: Example 3 (Higher of TCC and Mid Point) • Scenario 3: Five countries (higher PI-MAPP) • In 2012, Drug product A now sold in 5 countries: Italy ($10), France ($17), • Germany ($17), Switzerland ($17), US ($20) MIPC = $17 • Mid Point = $13.50 • Post-Interim MAPP is set by the Mid Point • N-NEAP (based on CPI-Adjustment Methodology) in 2012 is $13 • Impact on future requests for DIP application: IBP remains at $12.50 Post-Interim MAPP (2012) = $13.50 Final 2012 N-NEAP = $13

  26. Interim MAPP – Meaning and implications • A MAPP based on any test that includes a MIPC test is interim when the MIPC is based on data from less than 5 countries. • A post interim MAPP is calculated 3 years after intro or when the drug product is sold in five countries, whichever comes first. • The final N-NEAP will be the lower of the post-interim MAPP and the N-NEAP based on the CPI-Adjustment Methodology

  27. DIP Methodology

  28. Simplified DIP Methodology: Reminders Patentee acquires DIN from previous patentee prior to January 1, 2010: patentee to obtain original IBP from previous patentee for DIP applications Benefits at introduction: consider reporting transactions with and without benefits on separate lines in Form 2 Block 4 Pay attention to Form 2 Block 5 Canada price

  29. Regular DIP Methodology: Calculation of IBP* Block 5 Canada price increase < annual (one year) CPI Use lower of : annual (one year) CPI and % increase of Form 2 Block 5 Canada price

  30. Regular DIP Methodology: Calculation of IBP* No increase in Form 2 Block 5 Canada price for at least 3 years Use lower of: Cap % increase in Form 2 Block 5

  31. Regular DIP Methodology: Calculation of IBP* When Form 2 Block 5 Canada price increases every year, CPI-Adjustment Methodology considered. 2010 CPI 0.8412 X 1.045 = 0.8791 CAP 0.8606 X 1.027 = 0.8838 % Bl5 increase 0.8606 X 1.022 = 0.8795

  32. PMPRB 101

  33. SOLD OUT PMPRB 101 • Where? PMPRB office, 14th floor, 333 Laurier Avenue West, Ottawa • When? December 6, 2012 from 10:00 a.m. to 3:30 p.m. • For whom? Employees from pharmaceutical companies who need to understand PMPRB basic operations such as filing, calculation of intro prices and ongoing NEAPs • What? Introduction to PMPRB processes

  34. The different forms that need to be filed Section 82: Notification of Intent to Sell Form 1 Form 2 Overview of Filing Session for PMPRB 101 • Filing timelines • Reporting process

  35. Overview of Filing Session for PMPRB 101 • Failure to File • Common filing errors • Compliance Status Reports • Where to find the forms on the PMPRB website

  36. Overview of the Introductory Price Analysis Scientific Review • Submission Process for Scientific Data on New Drug Products • Human Drug Advisory Panel (HDAP) • Scientific Review Process • Levels of Therapeutic Improvement • Selection of Comparators • Selection of Dosage Regimens

  37. Overview of the Introductory Price Analysis Introductory Price Review • Introductory Price Tests • Median International Price Comparison (MIPC) • Therapeutic Class Comparison (TCC) • Mid-point • Reasonable Relationship (RR) • Highest International Price (HIPC) • Criteria for Investigation at Introduction • Communication of Results to Patentees

  38. PMPRB 101 Let’s Talk Numbers • Price Review of Existing Medicines • CPI Adjustment Methodology • Highest International Price Comparison Exchange Rates • Verification of International Prices • Calculating ex-factory prices Criteria for an investigation Application forms for the DIP Methodology

  39. Communication with Board Staff • Query to PMPRB Staff • Guidelines: Ginette Tognet Tel: (613) 954-8297 E-mail: ginette.tognet@pmprb-cepmb.gc.ca • Scientific and new meds: Catherine Lombardo Tel: (613) 952-7620 E-mail: catherine.lombardo@pmprb-cepmb.gc.ca • Filing Form 1 and 2: Beatrice Mullington Tel: (613) 952-2924 E-mail: beatrice.mullington@pmprb-cepmb.gc.ca • Investigation: Senior Regulatory Officer assigned to Company • Form 3: Lokanadha Cheruvu Tel: (613) 954-9812 E-mail: lokanadha.cheruvu@pmprb-cepmb.gc.ca • Website: Carol McKinley Tel: (613) 960-4550 E-mail: carol.mckinley@pmprb-cepmb.gc.ca • All other questions: 1-877-861-2350 pmprb@pmprb-cepmb.gc.ca

More Related